LIDDS’s Annual Report 2022 Published

Regulatory

Uppsala, 25 April, 2023 – The 2022 Annual report of LIDDS AB (publ) is now available on the company website.

The annual report is available in PDF format on the company website at: https://liddspharma.com/en/investors/financial-reports/

Printed copies can be ordered from LIDDS AB, Virdings allé 32B, SE- 754 50 Uppsala, or by e-mail: info@liddspharma.com

For additional information, please contact

Anders Månsson, CEO
Phone: +46 (0)70 860 47 38
E-mail: anders.mansson@liddspharma.com

Jenni Björnulfson, CFO
Phone: +46 (0)70 855 38 05
E-mail: jenni.bjornulfson@liddspharma.com

LIDDS’ Certified Adviser is Redeye AB

LIDDS in brief:

LIDDS is a Swedish drug delivery company based on the proprietary technology NanoZolid®. With NanoZolid®, LIDDS can formulate drugs for local/intratumoral administration, with a maintained and controlled release for up to six months. The technology is versatile, can be used across different drug classes and can solve problems within many indication areas, mainly within oncology. LIDDS offers the NanoZolid® technology to partners and has developed its own pipeline focused on oncology, where the technology enables delivery of a local and high drug dose, administered over time with very limited side effects. LIDDS has a broad pipeline with several projects in clinical development, both in early and late-stage clinical phase, and projects about to enter clinical development. The company is listed on Nasdaq First North Growth Market.

Attachments

LIDDS Årsredovisning 2022 SVE FINAL